The High-Dose Aldesleukin (IL-2) “Select” Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High-Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma

✍ Scribed by Jessica M. Clement; David F. McDermott

• Book ID: 119935423
• Publisher: CIG Media Group, LP.
• Year: 2009
• Tongue: English
• Weight: 107 KB
• Volume: 7
• Category: Article
• ISSN: 1558-7673
• DOI: 10.3816/cgc.2009.n.014